Growth factors activate phospholipases, causing the generation of diverse lipid metabolites with second messenger function. Among them, the phosphatidylcholine-preferring phospholipase D (PLD) has attracted great interest, since in addition to the transient activation by growth factors stimulation,
Phospholipase C–protein kinase C mediated phospholipase D activation pathway is involved in tamoxifen induced apoptosis
✍ Scribed by Soo-Jung Ahn; Mee-Sup Yoon; Shin Hyuk; Wonshik Han; Yong-Dal Yoon; Joong-Soo Han; Dong-Young Noh
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 294 KB
- Volume
- 89
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Tamoxifen (TAM) is the endocrine therapeutic agent the most widely used in the treatment of breast cancer, and it operates primarily through the induction of apoptosis. In this study, we attempted to elucidate the non‐ER mediated mechanism behind TAM treatment, involving the phospholipase C–protein kinase C (PLC–PKC) mediated phospholipase D (PLD) activation pathway, using multimodality methods. In TAM treated MCF7 cells, the PLC and PLD protein and mRNA levels increased. Phosphatidylethanol (PEt) and diacylglycerol (DAG) generation also increased, showing increased activity of PLD and PLCγ1. Translocation of PKCα, from cytosol to membrane, was observed in TAM treated cells. By showing that both PKC and PLC inhibitors could reduce the effects of TAM‐induced PLD activation, we confirmed the role of PKC and PLC as upstream regulators of PLD. Finally, we demonstrated that TAM treatment reduced the viability of MCF7 cells and brought about rapid cell death. From these results, we confirmed the hypothesis that TAM induces apoptosis in breast cancer cells, and that the signal transduction pathway, involving PLD, PLC, and PKC, constitutes one of the possible mechanisms underlying the non‐ER mediated effects associated with TAM. © 2003 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Imidazoline receptor antisera-selected protein (IRAS) is considered as a candidate for the I1-imidazoline receptor (I1R), but the signaling pathway mediated by IRAS remains unknown. In our study, the signal transduction pathways of IRAS were investigated in CHO cells stably expressing IRAS (CHO-IRAS
## Abstract It has recently been shown that the activation of protein kinase C (PKC) induces protein tyrosine phosphorylation in osteoblast‐like MC3T3‐E1 cells. We previously reported that the activation of PKC stimulates phosphatidylcholine‐hydrolyzing phospholipase D in these cells. In this study
We determined whether activation of phosphatidylinositol-specific phospholipase C (PI-PLC) and a subsequent increase in cytosolic calcium concentration ([Ca2+]i) was an obligatory signaling event mediating the increase in transendothelial permeability induced by bradykinin (BK) and alpha-thrombin (a
We investigated the regulatory mechanism of interleukin-6 (IL-6) synthesis induced by interleukin-1 (IL-1) in osteoblast-like MC3T3-E1 cells. IL-1 stimulated the secretion of IL-6 in a dose-dependent manner in the range between 0.1 and 100 ng/ml. Staurosporine and calphostin C, inhibitors of protein
## Abstract The effects of P2Y2 purinoceptor activation on c‐Fos expression and the signaling pathways evoked by extracellular ATP/UTP in HeLa cells were investigated. We found that P2Y2 activation induced c‐Fos protein and phosphorylated the extracellular signal‐regulated kinases 1 and 2 (ERK1/2).